Concepedia

Claire Brillac

CB

6

Publications

213

Citations

6

H-Index

2017

Active since

Affiliations

Sanofi (France)(Current)

Sanofi (United States)

National and Kapodistrian University of Athens

AVEO Oncology (United States)

Claire Brillac is an author at Sanofi (France) specializing in antibody engineering, translational medicine, and tumor biology.

ORCID

Top concepts

Publications per year

2017–2021

6

Publications

6

Preclinical Activity of SAR408701: A Novel Anti-CEACAM5–maytansinoid Antibody–drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors

Stéphanie Decary, Pierre‐François Berne, Céline Nicolazzi et al. · Clinical Cancer Research · 2020 · 74 citations · Full text

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Joseph Mıkhael, Joshua Richter, Ravi Vij et al. · Leukemia · 2020 · 51 citations · Full text

Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Tadamichi Denda, Daisuke Sakai, Tetsuya Hamaguchi et al. · Cancer Science · 2019 · 39 citations · Full text

Drug‐Disease Interaction and Time‐Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients

Jean‐Baptiste Fau, Raouf El‐Cheikh, Claire Brillac et al. · CPT Pharmacometrics & Systems Pharmacology · 2020 · 25 citations · Full text

Translational Model-Based Strategy to Guide the Choice of Clinical Doses for Antibody-Drug Conjugates

Marion Bouillon‐Pichault, Claire Brillac, Céline Amara et al. · The Journal of Clinical Pharmacology · 2017 · 14 citations

, , +26

Rows per page

1–5 of 6